Clinical trials · Washington
Myelodysplastic Syndromes clinical trials in Washington
We’re tracking 31 recruiting myelodysplastic syndromes studies with a site in Washington — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Washington
- NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Tacoma, WashingtonAges Up to 22 years - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT05732103RecruitingPhase 1/Phase 2
Testing CTX-712 for AML or high-risk MDS after prior treatment
This early-phase study tests CTX-712, a new cancer treatment, in people whose acute myeloid leukemia (AML) or certain high-risk blood cancers came back or did not respond to prior therapy. It may help shrink the cancer and control the disease by targeting it differently than standard treatments.
Seattle, WashingtonAges 18 years+ - NCT04375631RecruitingPhase 1
Study of chemo plus donor stem cell transplant for blood cancers
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
Seattle, WashingtonAges 18 years+ - NCT06641414RecruitingPhase 3
Lisaftoclax with azacytidine for higher-risk myelodysplastic syndrome
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
Edmonds, WashingtonAges 18 years+ - NCT06499285RecruitingPhase 3
Study of a new drug to treat anemia in adults with low to intermediate risk MDS who need transfusions
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
Issaquah, WashingtonAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Seattle, WashingtonAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Edmonds, WashingtonAges 18 years+ - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
Seattle, WashingtonAges 18 years+ - NCT03970096RecruitingPhase 2
Reduce graft-versus-host disease after stem cell transplant
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Seattle, WashingtonAges 1–60 - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Seattle, WashingtonAges 1–18 - NCT06928662RecruitingPhase 1/Phase 2
Chemo, radiation, and donor stem cell transplant for high-risk blood cancers
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
Seattle, WashingtonAges 18 years+ - NCT05320198RecruitingPhase 1/Phase 2
Testing DISC-0974 for anemia in myelofibrosis or MDS
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
Seattle, WashingtonAges 18 years+ - NCT04256317RecruitingPhase 2/Phase 3
Azacitidine pills with or without venetoclax for certain blood cancers
This study tests whether a pill form of azacitidine (ASTX030) helps people with myelodysplastic syndromes (MDS), CMML, or AML. Some groups may also receive venetoclax; the goal is better blood cancer control for people who aren’t good candidates for intensive chemotherapy.
Seattle, WashingtonAges 18 years+ - NCT06034275RecruitingPhase 1
Study of VIP943 for CD123-positive blood cancers
This trial tests a new drug called VIP943 for people with advanced acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), or myelodysplastic syndrome (MDS) whose cancer cells have a marker called CD123. It is for those who have tried all other treatments or cannot receive them.
Seattle, WashingtonAges 18 years+ - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Seattle, WashingtonAges 18 years+ - NCT07046078RecruitingPhase 2
Chemo, radiation, and donor transplant for older adults with high-risk AML
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Seattle, WashingtonAges 18 years+ - NCT06859424RecruitingPhase 2
Testing a new GVHD prevention method after donor stem cell transplant
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
Seattle, WashingtonAges 18–66 - NCT06834282RecruitingPhase 1
A study of CER-1236 for certain blood cancers
This trial tests an experimental cell therapy called CER-1236 for people with acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis. It aims to see if it can help treat these cancers.
Seattle, WashingtonAges 18–85 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Seattle, WashingtonAges Any age - NCT02143830RecruitingPhase 2
Stem cell transplant chemotherapy for Fanconi anemia
This Phase 2 study tests a stem cell transplant approach using adjusted chemotherapy doses for people with Fanconi anemia. It may help replace damaged bone marrow and treat blood problems like severe aplastic anemia, MDS, or leukemia.
Seattle, WashingtonAges 3 months+ - NCT06013423RecruitingPhase 2
Cord blood transplant with chemo and radiation for high-risk blood cancers
This trial tests a cord blood transplant after a reduced-intensity chemotherapy and radiation regimen for patients with high-risk blood cancers like leukemia, lymphoma, or MDS. The goal is to see if this approach can help destroy cancer cells and restore healthy blood cells.
Seattle, WashingtonAges 6 months–65 years
Myelodysplastic Syndromes trials by city in Washington
Where these studies are running in Washington
Institutions with a site for the recruiting myelodysplastic syndromes studies listed above.
- Fred Hutchinson Cancer Center · 16 studies
- Seattle Children's Hospital · 2 studies
- Ascentage Investigative Site
- Epic Care Emeryville
- Madigan Army Medical Center
- Mary Bridge Children's Hospital and Health Center
- Massive Bio SYNERGY-AI site
- Providence Sacred Heart Medical Center and Children's Hospital
What taking part in a myelodysplastic syndromes study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Myelodysplastic Syndromes trials in other states
Common questions
- Are there myelodysplastic syndromes clinical trials in Washington?
- Yes. We're currently tracking 31 recruiting myelodysplastic syndromes studies with a site in Washington, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a myelodysplastic syndromes study in Washington?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington to take part?
- Not necessarily. These studies have a site in Washington, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a myelodysplastic syndromes trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New myelodysplastic syndromes studies open in Washington regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.